VG Life Sciences Notes Major Achievements

VG Life Sciences Notes Major Achievements and New Grants in Third Quarter 2015

SANTA BARBARA, Calif.Oct. 13, 2015 /PRNewswire/ --

Dear Shareholders,

Here at VG Life Sciences (OTC-QB: VGLS), our mission is to save and improve lives through the development of transformative treatments for cancer, infectious diseases, and the chronic inflammation intrinsic to autoimmune diseases. We have made significant progress in a number of areas in the third quarter of 2015. We'd like to update you on our accomplishments.



On July 28, 2015 Edward Inscho, Ph.D., from the University of Alabama at Birmingham, made an important presentation at Texas A & M University on using the VGLS patented drug VG1177 in research focused on the impact of inflammatory processes on renal microvascular function and hypertension.

Chronic inflammation is linked to hypertension, and kidney injury.

"Continued research focused on the immune system involvement may open novel therapeutic targets for inflammatory kidney disease and hypertension," said Inscho.

VG1177 is a synthetic peptide that is an antagonist to the MHC Class II-associated invariant peptide (CLIP) for binding to the MHC peptide binding groove.

VGLS Chief Scientist M. Karen Newell-Rogers, Ph.D., an inventor of VG1177, postulates that self-peptide binding to MHC plays a key role in chronic inflammation and autoimmune diseases, including HIV/AIDS, hypertension, preeclampsia and traumatic brain injury.


As reported previously, we have completed the Phase I clinical trial of our combination cancer therapy conducted at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio. This trial involved patients with solid tumors and examined the safety and efficacy of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexavar®), co-developed by Bayer AG and Onyx Pharmaceuticals. VGLS holds Patent No. 9073985 covering the combination therapy used in this trial.

In Phase I, tumor reduction and stabilization was shown in a number of patients in the third and fourth cohorts, all of whom had higher doses of the combination therapy. The design of this clinical trial allowed us to conclude that these positive effects can be attributed to the combination therapy and not sorafenib alone.

The University of Texas is now starting a Phase II of this important clinical trial.

Auto Immune Diseases

Research has continued at our laboratory at Texas A & M University under the direction of VGLS Chief Scientist M. Karen Newell-Rogers, Ph.D.  In collaboration with research scientists from leading institutions around the country, Dr. Newell-Rogers is actively pursuing applications ofVG1177 in autoimmune diseases and chronic inflammatory conditions.

Additionally, our laboratory is testing three new peptides, VG1196, VG1197, and VG 1198, based on our chemist's recommendations to pursue a version of VG1177 with enhanced stability, tolerability and solubility.  These new peptides were received during the quarter from our pharmaceutical vendor Ambiopharm Inc.

Dr. Newell-Rogers was awarded $250,000 from the CURE Epilepsy Foundation to fund her research on the role of the immune system in post-traumatic epilepsy.  She was also awarded$100,000 from an anonymous donor for further Lyme research. Both of these grants will test the efficacy of VG1177 in these diseases and its ability to reduce inflammation.


The Company's SEC attorney has recommended that VGLS increase the total number of authorized shares for compliance purposes and future planning.  The total number of authorized shares will be increased to 300,000,000.

In Conclusion

The third quarter 2015 was busy and productive as VGLS continued to pursue its goals of moving its cancer therapy into Phase II clinical trials and expanded the research of its Targeted Peptide Technology (TPT) in combating autoimmune and infectious diseases.

In the fourth quarter of 2015 we will be focusing on completing a number of important studies so that we will be positioned to restart the animal safety studies of TPT in early 2016.  Meanwhile, we will keep you updated with the latest news and exciting developments through company press releases.

Be well,

John P. Tynan
President & CEO 
VG Life Sciences, Inc.

About VG Life Sciences Inc.

Santa Barbara, California-based VG Life Sciences, Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, inflammatory disease, and autoimmune disorders. VGLS controls over 40 U.S. and international patents and pending patents protecting its exclusive biotech platform technologies.

For more information and upcoming events, visit, or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements: This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world.  Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences will be achieved.

Terri Somers
Somers Media
Phone: (619) 991-2369

SOURCE VG Life Sciences 

Note: We deliberately do not use the terms "buy", "hold" or "sell", but instead use "neutral", "upgrade" and "downgrade" in our QuickPicks list. This is based on our philosophy that our QuickPicks list does not promote the buying and selling of specific stocks, but wants to assist with your overall investment decision and provide rational guidance.  Please note the stocks that we have dropped when we adjusted the portfolio. 
Remember, in addition to our own research for our QuickPicks section, we pour over charts, third party analyst opinions and reports from such firms and individuals that we respect, in order to reach as much of a market consensus as possible. Naturally, on occasion the investment thesis for certain picks may break down. When that happens, we try and let you know as quickly as possible. Again, do not rely on our guidance alone, but exercise your own due diligence and stick to your trading plan.

Please try out our new service We would appreciate if you could please pass this on to your friends and colleagues and we always appreciate your feedback and comments.
About SWI
SWI is a leading-edge PR, Information Marketing and Research Service with a highly frequented web site, its "Rise Above The Noise" newsletter and SWI Research  site These services provide you with information and research on new and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst blogs and opinions of leading Wall Street firms that we respect and frequently sample. The weekly SWI QuickPicks  Ratings Report keeps you informed about newly initiated stocks and potential upgrades and downgrades by us in our QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any one of these stocks.  You can conveniently follow the live links for each of these stocks on for more detail.  SWI's periodical "Portfolio Performance Report" frequently updates the performance of the stocks that we have purchased and are holding in the SWI Portfolio, as published on our WatchIndex page. Please do not miss the wealth of frequently updated news, research reports, financial white papers and other valuable information elsewhere on SWI. Watch a full range of CEO and analyst interviews on our Strategic Partner site  
Google +
Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy, or completeness, or fitness for a purpose (investment or otherwise) of the information provided in the publications of its Newsletter, Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. We have not been compensated by any of the companies presented on this list. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its newsletter or on its web sites. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp